Arch Biopartners' market value is the price at which a share of Arch Biopartners trades on a public exchange. It measures the collective expectations of Arch Biopartners investors about its performance. Arch Biopartners is trading at 0.88 as of the 27th of December 2025. This is a 3.3 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.88. With this module, you can estimate the performance of a buy and hold strategy of Arch Biopartners and determine expected loss or profit from investing in Arch Biopartners over a given investment horizon. Check out Arch Biopartners Correlation, Arch Biopartners Volatility and Arch Biopartners Alpha and Beta module to complement your research on Arch Biopartners.
Please note, there is a significant difference between Arch Biopartners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arch Biopartners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arch Biopartners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Arch Biopartners 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arch Biopartners' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arch Biopartners.
0.00
10/28/2025
No Change 0.00
0.0
In 2 months and 2 days
12/27/2025
0.00
If you would invest 0.00 in Arch Biopartners on October 28, 2025 and sell it all today you would earn a total of 0.00 from holding Arch Biopartners or generate 0.0% return on investment in Arch Biopartners over 60 days. Arch Biopartners is related to or competes with Innate Pharma, Brii Biosciences, Scancell Holdings, JW (Cayman), NervGen Pharma, Ascend Wellness, and Santhera Pharmaceuticals. Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact More
Arch Biopartners Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arch Biopartners' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arch Biopartners upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arch Biopartners' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arch Biopartners' standard deviation. In reality, there are many statistical measures that can use Arch Biopartners historical prices to predict the future Arch Biopartners' volatility.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Arch Biopartners. Your research has to be compared to or analyzed against Arch Biopartners' peers to derive any actionable benefits. When done correctly, Arch Biopartners' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Arch Biopartners.
Arch Biopartners Backtested Returns
Arch Biopartners secures Sharpe Ratio (or Efficiency) of -0.0102, which signifies that the company had a -0.0102 % return per unit of standard deviation over the last 3 months. Arch Biopartners exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Arch Biopartners' mean deviation of 2.33, and Risk Adjusted Performance of (0.05) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.3, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Arch Biopartners' returns are expected to increase less than the market. However, during the bear market, the loss of holding Arch Biopartners is expected to be smaller as well. At this point, Arch Biopartners has a negative expected return of -0.0339%. Please make sure to confirm Arch Biopartners' treynor ratio, day median price, and the relationship between the information ratio and kurtosis , to decide if Arch Biopartners performance from the past will be repeated at some point in the near future.
Auto-correlation
0.61
Good predictability
Arch Biopartners has good predictability. Overlapping area represents the amount of predictability between Arch Biopartners time series from 28th of October 2025 to 27th of November 2025 and 27th of November 2025 to 27th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arch Biopartners price movement. The serial correlation of 0.61 indicates that roughly 61.0% of current Arch Biopartners price fluctuation can be explain by its past prices.
Correlation Coefficient
0.61
Spearman Rank Test
0.33
Residual Average
0.0
Price Variance
0.0
Arch Biopartners lagged returns against current returns
Autocorrelation, which is Arch Biopartners otc stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Arch Biopartners' otc stock expected returns. We can calculate the autocorrelation of Arch Biopartners returns to help us make a trade decision. For example, suppose you find that Arch Biopartners has exhibited high autocorrelation historically, and you observe that the otc stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values
Timeline
Arch Biopartners regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Arch Biopartners otc stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Arch Biopartners otc stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Arch Biopartners otc stock over time.
Current vs Lagged Prices
Timeline
Arch Biopartners Lagged Returns
When evaluating Arch Biopartners' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Arch Biopartners otc stock have on its future price. Arch Biopartners autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Arch Biopartners autocorrelation shows the relationship between Arch Biopartners otc stock current value and its past values and can show if there is a momentum factor associated with investing in Arch Biopartners.
Arch Biopartners financial ratios help investors to determine whether Arch OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arch with respect to the benefits of owning Arch Biopartners security.